Immutep Limited announced new data has been published in poster presentations at the Society for Immunotherapy of Cancer Annual Meeting 2021 which took place from 10-14 November 2021 in the US. The new data relates to the Company's Phase IIb AIPAC trial and Part C of its Phase II TACTI-002 study. In addition, a poster presentation of the trial design of the Company's new randomised Phase IIb study in 1st line HNSCC was also presented at SITC. In addition to the final OS data announced on 10 November 2021, Immutep reports new Quality of Life data from AIPAC. QoL is a secondary endpoint of the study. In the total trial population, a statistically significant QoL preservation was observed in the first 6 months in the efti group of patients who were treated with efti in combination with paclitaxel. This compares favourably to the comparator group (paclitaxel and placebo) where a significant deterioration in these measures were reported at 6 months QoL is generally very important for patient compliance and forms part of reimbursement discussions after any potential marketing approval. As previously announced, the AIPAC trial demonstrates a statistically significant and clinically meaningful OS benefit in now three prespecified patient subgroups. A majority of patients fall into at least one of the patient subgroups and therefore derive a statistically significant benefit. Patients under the age of 65 years reported a median OS of 22.3 months compared to 14.8 months in the comparator group, indicating an absolute survival benefit of +7.5 months favoring the efti group. Patients with a low monocyte count at the commencement of the study (representing 21.9% of patients in the efti group) reported a median OS of 32.5 months compared to 12.9 months in the comparator group, indicating an absolute survival benefit of +19.6 months favoring the efti group. Patients with a more proliferating tumor cell type expressing more neo-antigens, characterised as luminal B reported a median OS of 16.8 months compared to 12.6 months in the comparator group, indicating an absolute survival benefit of +4.2 months favoring the efti group.